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Main Text {#sec1}
=========

Chemical Approaches to Maintain Stem Cell Self-Renewal {#sec1.1}
------------------------------------------------------

Embryonic stem cells (ESCs), the *ex vivo* equivalent of the epiblast lineage of the blastocyst, were originally derived using medium containing serum with a feeder layer of mitotically inactivated fibroblasts. Later, leukemia inhibitory factor (LIF), and bone morphogenetic protein 4 (BMP4)-SMAD signals, which are associated with feeder layer cells, were found to be essential for maintaining mouse ESC (mESC) self-renewal ([@bib42], [@bib66]). From a high-content screen, we identified a new 3,4-dihydropyrimido(4,5-d)pyrimidine analog, pluripotin/SC1, which could maintain mESCs in the undifferentiated, pluripotent state under chemically defined conditions in the absence of feeder cells, serum, LIF, and BMP4 ([@bib11]). Mechanistic studies revealed that SC1 directly binds and inhibits two target proteins involved in the differentiation-inducing signaling, extracellular signal-regulated kinases (ERK) and Ras GTPase-activating protein. This study provided a conceptual advance that mESC self-renewal can be achieved through inhibiting the differentiation-inducing signals, which highlights the power of chemical approaches in dissecting the complex biology of stem cells. Later, [@bib67] reported 2i medium, using CHIR99021, a glycogen synthase kinase-3 (GSK-3) inhibitor, and PD0325901, a MEK1/2 inhibitor, to maintain mESC self-renewal.

Chemical approaches were also used to facilitate hESC self-renewal. [@bib61] found Y-27632, a selective Rho-associated kinase (ROCK) inhibitor, which promotes the survival of dissociated single-cell hESCs without the loss of pluripotency. Consistently, [@bib63] identified thiazovivin from a high-content chemical screen, which increases hESC single-cell survival with enhanced self-renewal. Interestingly, affinity chromatography experiments revealed that thiazovivin enhances E-cadherin stability and cell-cell interactions through the inhibition of ROCK.

Synthetic Small Molecules Facilitate Achieving "Stemness" {#sec1.2}
---------------------------------------------------------

In last two decades, a major breakthrough in the stem cell field is cellular reprogramming, in which lineage-committed cells overcome their intrinsic lineage-restriction upon exposure to a specific set of signals, and reverse back to the multipotent or even pluripotent stage. In 2004, we performed a high-throughput screen using C2C12 myoblasts and identified reversine, a 2,6-disubstituted purine, which reverses lineage-committed myoblasts back to the multipotent stage. The reversine-treated myoblasts can efficiently differentiate into osteoblasts and adipocytes only upon exposure to the appropriate differentiation conditions ([@bib12]) ([Table 1](#tbl1){ref-type="table"}). [@bib54] reported the groundbreaking work to reprogram fibroblasts to the pluripotent stage by using overexpression of *Oct4*, *Sox2*, *Klf4*, and *c-Myc*. Subsequently, many chemical screens were carried out to identify the small molecules to replace the transcriptional factors in a stepwise manner. Using a phenotypic screen with *Oct4* promoter-driven GFP expression, [@bib50] identified BIX-01294 and BayK8644, which enable reprogramming of *Oct4/Klf4*-transduced mouse embryonic fibroblasts. In a focused screen, [@bib25] found that valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, improves reprogramming efficiency and induces reprogramming in the presence of *c-Myc*. Moreover, VPA enables the reprogramming of primary human fibroblasts with only two factors, *Oct4* and *Sox2* ([@bib26]). Through another chemical screen, kenpaullone was identified to enable the reprogramming of mouse embryonic fibroblasts in the absence of *Klf4* ([@bib34]). [@bib27] identified RepSox, which replaces *Sox2* during reprogramming by inhibiting transforming growth factor β (TGF-β) signaling. [@bib33] reported that the combination of VPA, tranylcypromine, CHIR99021, and 616452, was sufficient to induce reprogramming with a single transcription factor, *Oct4*. The treatment of EPZ004777, an inhibitor of the histone H3K79 methyltransferase DOT1-like, significantly increases the yield of induced pluripotent stem cell (iPSC) colonies, and could be substituted for *Klf4* and *c-Myc* ([@bib43]). Finally, [@bib23] reported a combination of seven compounds identified from a chemical screen, including VPA, tranylcypromine, CHIR99021, 616452, forskolin, 3-deazaneplanocin, and PD0325901, which induces mouse somatic cell reprogramming to PSCs in the absence of transgene overexpression.Table 1Summary of Compounds Identified from Stem Cell-Based ScreensCompoundStarting PopulationScreening ReadoutBiological Process AffectedMechanism of ActionReferences**Cellular Reprogramming**ReversineC2C12 cellsalkaline phosphatase as an osteoblast markerreprogramming from lineage-committed myoblasts to multipotent stagea dual inhibitor of MEK1 and nonmuscle myosin II heavy chain[@bib12]BIX-01294*Oct4*, *Klf4-*transduced mouse embryonic fibroblasts (MEFs)ESC colony and staining with alkaline phosphatase as a pluripotency markerreprogramming of *Oct4/Klf4*-transduced mouse embryonic fibroblastsa potential G9a histone methyltransferase inhibitor[@bib50]BayK8644a potential L-channel calcium agonistValproic acid*Oct4-*, *Sox2-*, *Klf4-*, and *c-Myc-*transduced MEFsthe percentage of Oct4-GFP^+^ cellsimprove reprogramming efficiency of mouse and human fibroblastsa potential histone deacetylase inhibitor[@bib25], [@bib26]Kenpaullone*Oct4-*, *Sox2-*, and *c-Myc-*transduced MEFs*Nanog-Luc* activityinduce reprogramming in the absence of *Klf4*a potential GSK-3β inhibitor[@bib34]RepSox*Oct4*-, *Klf4*-, and *c-Myc*-transduced MEFsthe number of Oct4-GFP + coloniesinduce reprogramming in the absence of Sox2inhibit TGF-β signaling[@bib27]Forskolin*Sox2*-, *Klf4*-, and *c-Myc*-transduced MEFsthe number of Oct4-GFP + coloniesinduce reprogramming in the absence of Oct4a potential cAMP activator[@bib23](S)-(+)-Dimethindene maleateprimed H9 hESCsactivate the *OCT4* distal enhancersupport the conversion and maintenance of dome-shaped hPSCs from primed hPSCsa potential M~2~ muscarinic receptor antagonist[@bib64]minocycline hydrochloridea potential metalloproteinase inhibitor**Directed Differentiation**PD407824C2C12 cells*Id2-Luc* reportersynergize with BMP4 to direct hPSC differentiation toward mesoderm or cytotrophoblast stem cellsinhibit checkpoint kinase 1[@bib19]AtauprimidemESCsimmunostaining using SOX17 antibodyprime mouse and human ESC differentiationinteract with NME2 and inhibit nuclear localization[@bib70]IDE1mESCSox17 promoter-driven tdTomatoinduce nearly 80% of ESCs to form definitive endodermactivate TGF-β signaling[@bib2]IDE2Indolactam VhESC-derived endodermal cellsimmunostaining using PDX1 antibodyinduce differentiation toward pancreatic progenitorsactivate PKC[@bib10]H1152hESC-derived pancreatic progenitorsimmunostaining using insulin antibodyincrease the generation of insulin-secreting cellsinhibit ROCKII[@bib20]CI-994hPSC-derived immature hepatocytesalbumin-Venus reporterpromote hPSC differentiation toward hepatocyte-like cellsinhibit histone deacetylase[@bib31]SU5402\
CHIR99021\
DAPThPSC-derived neuroectodermimmunostaining using PAX6 and β3-tubulin antibodiespromote hPSC differentiation toward neuronsa potential VEGFR inhibitor[@bib9]a potential GSK-3β inhibitora potential Notch inhibitorSelamectinmESCimmunostaining using tyrosine hydroxylase antibodytransform mPSCs into neuronsa potential GABA~A~ agonist[@bib53]PhenanthrolinehESC-derived lens placode*SIX1 H2B*::*GFP* reporterpromote differentiation from nonneural ectoderm to cranial placodea potential metalloprotease inhibitor[@bib56]KY02111monkey ESCsαMHC promoter-driven EGFPPSC differentiation toward cardiomyocytesNA[@bib39]Sodium nitroprussidemESC-derived mesodermal cellsCCS:lacz reporterpromote the generation of cardiac Purkinje fiber-like cellsincrease intracellular cAMP[@bib58]**Stem Cell-Based Disease Models**SKF-86466wild-type and familial dysautonomia iPSC-derived neural crest cellsalamarBlue to detect cell survival\
qRT-PCR to detect *IKBKAP* expressionrescue IKAP protein expression and the disease-specific loss of autonomic neuronal marker expressiona potential α~2~-adrenoceptor antagonist[@bib30]Kenpaullonewild-type and SOD1G93A HB9::GFP mESC-derived motor neuronimaging-based assay to count GFP^+^ cell numberprolong the healthy survival both mouse and human motor neuronsa potential dual inhibitor of GSK-3 and HGK kinases[@bib65]Alsterpaullonefibroblasts from parental SMA carriersimmunostaining using SMN antibodyincrease cellular SMNa potential GSK-3 inhibitor[@bib36]E34a co-culture of mESC-derived motor neurons, astrocytes, and interferon-γ- and lipopolysaccharide-activated microglial cellsthe total neurite length of all neurites of the motor neuronsprevent the neurons from cytokine and lipopolysaccharide-induced degenerationinhibit nitric oxide synthase[@bib22]Pepstatin A*EDNRB*-null mutant hESC-derived enteric nervous system precursorscell migration assayrescue loss of *EDNRB*-induced cell migration defectsinhibit BACE2[@bib18]AvermectinsTS21 iPSC-derived cortical neuronsthe activity of lactate dehydrogenase in mediumincrease the relative production of short Aβ peptides at the expense of longer, potentially more toxic peptidesNA[@bib4]Gardiac glycosidesfamilial hypercholesterolemia iPSC-derived hepatocyte-like cellsELISA-based assay to detect apolipoprotein B (apoB) productionreduce the production of apoBpotential inhibitors of the membrane sodium-potassium (NA^+^-K^+^) pump[@bib7]T5524*CDKAL1*^*−/−*^ hESC-derived pancreatic β-like cellsstaining with PI and insulin antibodyrescues loss of *CDKAL1* induced increased sensitivity to glucolipotoxcityinhibit the FOS/JUN pathway[@bib68]Galunisertib*GLIS3*^*−/−*^ hESC-derived pancreatic β-like cellsstaining with PI and insulin antibodyrescues loss of *CDKAL1* induced pancreatic β cell deathinhibit TGF-β pathway[@bib1]EmricasanhNPCscaspase-3/7 activity assayblock ZIKV-induced hNPC deatha pan-caspase inhibitor[@bib62]Niclosamideinhibits ZIKV replicationNAHippeastrine hydrobromidehNPCsstaining with ZIKV antibodyeliminate ZIKV infectionNA[@bib69]Geneticinfamilial adenomatous polyposis-iPSC-derived colonic organoidsstaining with CDX2 and Ki67 antibodiesrescue early stop codon caused APC protein decrease and increased cell proliferationNA[@bib13][^1]

In addition to cellular reprogramming, chemical screens were used to identify the compounds that facilitate the conversion between prime and naive pluripotent status. By screening compounds that activate the *OCT4* distal enhancer, [@bib64] established a minimal condition consisting of human LIF, CHIR99021, (S)-(+)-dimethindene maleate, and minocycline hydrochloride. This minimal condition supports the conversion and long-term maintenance of extended PSCs, which are capable of chimerizing both embryonic and extraembryonic tissues.

Directed hPSC Differentiation Using Chemical Approaches {#sec1.3}
-------------------------------------------------------

Human pluripotent stem cells (hPSCs) provide unlimited starting material to generate differentiated cells that can be used to build a functional organ. Essential to this pursuit is an efficient way to differentiate hPSCs into specific types of mature cells. The rational-based chemical approach has been widely used to manipulate the key pathways involved in PSC differentiation. For example, CHIR99021, which activates the Wnt pathway, is commonly used to promote hPSC differentiation ([@bib15]). Chambers and coworkers found that the combination of SB431542, a TGF-β inhibitor, and, dorsomorphin, a BMP inhibitor, efficiently induces hESC differentiation toward the neural lineage ([@bib8], [@bib28]). [@bib32] reported that the combination of CHIR99021, SB431542, and compound E can efficiently convert hESCs into homogeneous primitive neuroepithelium. [@bib18] found that CHIR99021 promotes the differentiation to neural crest, and that retinoic acid facilitates differentiation to enteric neural crest lineages. In addition, retinoic acid, LDN193189 (a BMP pathway inhibitor), KAAD-cyclopamine (a sonic hedgehog pathway inhibitor) are used to promote pancreatic induction from hESCs ([@bib14]). Although chemical agonists and antagonists provide powerful tools for hPSC differentiation, chemical agonists of several key development pathways, such as BMP, TGF-β, epidermal growth factor (EGF), and fibroblast growth factor (FGF), are still missing. Using a high-throughput screening platform based on C2C12 cells containing *Id2-Luc* reporter, we discovered PD407824, a checkpoint kinase 1 inhibitor that increases the sensitivity of cells to sub-threshold BMP4. We showed the utility of PD407824 in the directed differentiation of hESCs toward mesoderm or cytotrophoblast stem cells ([@bib19]).

Although rational-based chemical approaches have provided useful tools to induce hPSC differentiation, the molecular mechanism controlling organogenesis is not fully understood. Screening-based chemical approaches can also be applied to identify the small molecules directing stem cell differentiation ([Figure 1](#fig1){ref-type="fig"}). More importantly, the identified small molecules function as tools to discover the pathways controlling cell fate decision. For example, [@bib16] reported a high-throughput screen for the identification of compounds regulating self-renewal and differentiation in hESCs. By monitoring SOX17 expression, [@bib70] screened 20,000 compounds and identified stauprimide, which promotes efficient induction of SOX17 in both mouse and human ESCs synergistically with low concentrations of activin A. Using *Sox17* promoter-driven tdTomato as a reporter, [@bib2] screened 4,000 compounds and found two small molecules, inducer of definitive endoderm 1 (IDE1) and IDE2, that induce endoderm differentiation in both mESCs and hESCs. In addition, we performed a high-content chemical screen using hESC-derived definitive endoderm and identified (−)-indolactam V, a protein kinase C (PKC) activator, which promotes the generation of pancreatic progenitors ([@bib10]). Now, a PKC activator has become a standard component of most pancreatic β cell differentiation protocols ([@bib35], [@bib44], [@bib48], [@bib59]). Recently, we screened 2,000 compounds and found that H1152, a ROCKII inhibitor, increases the generation of insulin-secreting cells from hPSCs and improves β cell maturation ([@bib20]). Using an albumin-Venus reporter line, [@bib31] identified, CI-994, an HDAC inhibitor that promotes hPSC differentiation toward hepatocyte-like cells.Figure 1Summary of Small Molecules Regulating Pluripotent Stem Cell Differentiation

Both high-throughput and focused chemical screens were used to develop compounds or compound combinations directing hPSC differentiation to ectodermal lineages. Using a focused screen, [@bib9] developed a combination of five chemical pathway inhibitors, LDN193189 and SB431542, SU5402, CHIR99021, and DAPT, which yields hPSC-derived neurons at \>75% efficiency. [@bib53] reported a high-content screen, which revealed that selamectin, an anti-helminthic therapeutic compound, promotes neural differentiation of PSCs. A focused screen by combinatorial application of six pathway inhibitors revealed that XAV939 promotes anterior central nervous system identity; SU5402 and PD0325901 accelerate hPSC differentiation toward neuroectodermal lineages; and the highly transient anterior neuroectodermal precursor state is driven toward post-mitotic cortical fates in the presence of DAPT and SU5402/PD0325901 ([@bib46]). [@bib56] screened the LOPAC library (Sigma) and identified phenanthroline, a metal chelator that can act as a metalloprotease inhibitor, enhances cranial placode differentiation.

Finally, high-throughput or high-content screens also facilitate discovery of compounds inducing mesodermal differentiation. A cell-based screen led to the discovery of KY02111, which promotes hPSC differentiation to cardiomyocytes ([@bib39]). We carried out a high-throughput screen using CCS:lacz and Contactin2:egfp reporter ESC lines, and discovered sodium nitroprusside efficiently promotes the generation of cardiac Purkinje fiber-like cells ([@bib58]).

hPSC-Derived Cells for Disease Modeling and Drug Screening {#sec1.4}
----------------------------------------------------------

Patient-specific hPSCs represent a novel system for modeling human genetic diseases, which can be adapted to a high-throughput/content manner to screen for gene/mutation-specific drug candidates. The identified drug candidates will also facilitate dissecting entangled mechanisms under specific pathological settings. For example, [@bib30] reported a high-content screen using neural crest precursors derived from iPSCs that were generated from individuals with familial dysautonomia, a rare, fatal genetic disorder affecting neural crest lineages. One hit compound, SKF-86466, rescues IKAP protein expression and the disease-specific loss of autonomic neuronal marker expression. By applying a small-molecule survival screen using motor neurons from both wild-type and mutant *SOD1* (a gene associated with amyotrophic lateral sclerosis) mESCs, [@bib65] discovered that kenpaullone, a dual inhibitor of GSK-3 and HGK (hematopoietic progenitor kinase) kinases, prolongs the healthy survival both mouse and human motor neurons. Spinal muscular atrophy results from mutations that lead to low levels of the ubiquitously expressed protein, survival of motor neuron (SMN). [@bib36] executed an image-based screen and discovered compounds targeting the receptor tyrosine kinase-phosphatidylinositol 3-kinase-AKT-GSK-3 signaling cascade, which increase cellular SMN. A neuroprotective screen was carried out by adding interferon-γ- and lipopolysaccharide-activated microglial cells into the co-culture of mESC-derived motor neurons and astrocytes. This screen identified a number of neuroprotective small molecules that prevented the neurons from degeneration through diverse mechanisms, including inhibition of nitric oxide production by microglia, stimulation of the nuclear factor erythroid 2-related factor 2 pathway in microglia and astrocytes, and direct protection of neurons from cell death ([@bib22]). By modeling Hirschsprung disease-related migration defects using *EDNRB*-null hESC-derived mutant enteric nervous system precursors, we identified pepstatin A as a candidate therapeutic target for the treatment of Hirschsprung disease ([@bib18]). Amyloid precursor protein (APP) processing and the accumulation of APP-derived amyloid β peptides are key processes in Alzheimer\'s disease. [@bib4] designed a phenotypic chemical screen to identify modulators of APP processing in trisomy 21/Down syndrome neurons, a complex genetic model of Alzheimer\'s disease. Avermectins, which are commonly used anthelmintics, were found to increase the relative production of short Aβ peptides at the expense of longer, potentially more toxic peptides. Finally, using hepatocyte-like cells generated from homozygous familial hypercholesterolemia iPSCs, [@bib7] identified cardiac glycosides that can potentially be repurposed to lower serum low-density lipoprotein cholesterol.

In addition to modeling monogenic diseases, hPSC-derived cells can also be used to study the complicated diseases caused by a combination of genetic susceptibility and environmental factors. Genome-wide association studies (GWAS) have generated a large database of disease-associated SNPs and loci. One major challenge is to construct a robust system to systematically evaluate the role of these SNPs/loci using disease-relevant cells. Using isogenic hESC-derived pancreatic β-like cells, we found that mutations in *CDKAL1*, *KCNQ1*, and *KCNJ11*, diabetes-associated genes identified from GWAS, led to impaired glucose secretion. *CDKAL1* mutant insulin^+^ cells were also hypersensitive to glucolipotoxicity. A high-content chemical screen identified T5524 that rescues *CDKAL1*-specific defects *in vitro* and *in vivo* by inhibiting the FOS/JUN pathway ([@bib68]). Using these isogenic mutant hESCs, we found an unexpected interaction of two diabetes-associated genes, *CDKAL1* and *metallothionein* 1E *(MT1E)*. Forced *MT1E* expression rescues both hypersensitivity of *CDKAL1* mutant cells to glycolipotoxicity and pancreatic β cell dysfunction ([@bib21]). We also discovered the haploinsufficiency and dosage-sensitive requirements for *GATA6* and *GATA4*, two diabetes-associated genes, in the formation of both definitive endoderm and pancreatic progenitor cells ([@bib51]). Finally, we studied *GLIS3*, one of the only two genes associated with type 1, type 2, and neonatal diabetes. Using a "minimal component" protocol to generate mono-hormonal pancreatic β-like cells, we discovered that *GLIS3*^*−/−*^ hESCs show impaired differentiation with significant death of β-like cells. Furthermore, we performed a high-content chemical screen and identified a drug candidate targeting the TGF-β pathway, which rescues mutant *GLIS3*-associated β cell death both *in vitro* and *in vivo* ([@bib1]). These examples highlight the power of isogenic hPSCs to evaluate GWAS-identified genetic factors and to identify novel gene/mutation-specific drug candidates for precision medicine.

Finally, hPSC-derived cells also facilitate the drug discovery and evaluation for infectious diseases. A focused screen using hiPSC-CMs infected with a luciferase-expressing coxsackievirus B3 strain was used to evaluate anti-viral compounds including interferon β1, ribavirin, pyrrolidine dithiocarbamate, and fluoxetine ([@bib49]). A recent large outbreak first observed in Brazil brought Zika virus (ZIKV) to the forefront of public health attention. ZIKV infection is associated with an increased incidence of congenital defects, most prominently microcephaly ([@bib40], [@bib47]). In infected adults, ZIKV is associated with serious neurological complications such as meningoencephalitis and myelitis ([@bib5], [@bib6], [@bib38], [@bib45]). The World Health Organization and the NIH have compelled the scientific community to find solutions to the ZIKV threat. [@bib62] used hPSC-derived human cortical neural progenitors (hNPCs) to screen for anti-ZIKV drugs, and identified emricasan, a pan-caspase inhibitor, which protects hNPCs; cyclin-dependent kinases inhibit ZIKV replication; and niclosamide inhibits ZIKV replication. Concurrently, we performed a high-content screen and identified a novel anti-ZIKV compound, hippeastrine hydrobromide. Strikingly, hippeastrine hydrobromide suppresses viral propagation when administered to adult mice with active ZIKV infection, highlighting its therapeutic potential ([@bib69]).

hPSC-Derived 3D Organoids for Disease Modeling and Drug Screening {#sec1.5}
-----------------------------------------------------------------

In last decade, significant progresses has been made in 3D organoids. Strategies have been reported to differentiate hPSCs to 3D self-organizing organoids representing intestinal ([@bib52]), gastric ([@bib37]), brain ([@bib29]), liver ([@bib55]), lung ([@bib17]), pancreas ([@bib24]), and esophageal ([@bib57]) "mini-organs." Concurrently, we ([@bib13], [@bib41]) reported strategies to efficiently generate colonic organoids (COs) from hESCs. We made COs from the iPSCs derived from familial adenomatous polyposis (FAP) patients, which show enhanced WNT activity and increased epithelial cell proliferation ([Figure 2](#fig2){ref-type="fig"}). A focused screen identified geneticin targets abnormal WNT activity and thereby corrects the deregulated proliferation specific to FAP COs ([@bib13]). In addition to hPSC-based organoids, organoids derived from primary tumor tissues were also used for drug screens. [@bib3] developed a platform to propagate primary liver cancer (PLC) organoids. Screening using PLC-derived organoids identified an ERK inhibitor, SCH772984, as a potential therapeutic agent for PLC. Finally, we evaluated the anti-ZIKV compounds identified from a chemical screen and showed that hippeastrine hydrobromide rescues ZIKV-induced growth and differentiation defects in human fetal-like forebrain organoids, which highlights the value of human forebrain organoids in long-term evaluation of drug candidates in infectious diseases ([@bib69]).Figure 2Projection Image of Colonic Organoids Derived from FAP-iPSCsRed, CDX2; green, CCND1.

Humanized Animal Models for Long-Term *In Vivo* Drug Evaluation {#sec1.6}
---------------------------------------------------------------

Animal models have proven to be a powerful tool in drug discovery. However, due to the species differences, some animal models fail to precisely predict the clinical outcome, which is one of the major reasons of the high failure rate of clinical trials. There is a strong need to develop more predictive *in vivo* models to evaluate the efficacy, pharmacokinetic profile, and toxicological properties of leading compounds. Humanized mice carrying hPSC-derived cells will provide a powerful tool to evaluate the long-term *in vivo* efficacy of drug candidates on human cells. In our recent studies, we created humanized mice carrying hESC-derived pancreatic β-like cells. The mouse pancreatic β cells were destroyed by the administration of streptozotocin. Thus, the humanized mice depend on the transplanted human pancreatic β-like cells to maintain glucose homeostasis. We found that the mice transplanted with *CDKAL1*^*−/−*^ hESC-derived cells show impaired glucose secretion, coinciding with defective glucose homeostasis. The humanized mice were applied to evaluate the drug candidate identified from a high-content screen. We found that T5224 treatment significantly increases the level of insulin secretion and restores the capacity of the humanized mice to maintain glucose homeostasis ([@bib68]). In another study using humanized mice transplanted with *GLIS3*^*−/−*^ hESC-derived pancreatic β-like cells, we found that galunisertib rescues cell death induced by loss of *GLIS3 in vivo* ([@bib1]). Using avatar mice harboring hepatocyte-like cells generated from homozygous familial hypercholesterolemia iPSCs, [@bib7] showed that cardiac glycosides reduce the production of apolipoprotein B in the serum of humanized mice. Finally, [@bib60] used xenotransplanted mice carrying RAS mutant organoids to confirm the growth arrest effect of pan-HER/MEK combination therapy.

Conclusion and Prospective {#sec1.7}
--------------------------

High-throughput/content chemical screening is an emerging, critical approach to identify the small molecules controlling stem cell self-renewal, differentiation, and reprogramming. Using the small molecules identified from focused or unbiased screens, significant progress has been made to derive functional cells or organoids from hPSCs. However, several issues remain to be addressed to apply chemical approaches for broader applications. First, a better chemical toolkit to manipulate developmental pathways, such as chemical agonists of BMP, TGF-β, EGF, and FGF signals, are required. Second, additional chemical screens are needed to identify small molecules inducing differentiation to some poorly characterized cell types, such as cells in the cardiac conduction system, neuroendocrine cells, etc. Third, maturation is still a major concern for most directed differentiation protocols. With the appropriate experimental design, chemical screens will expedite the development of strategies promoting cell maturation.

hPSC-derived cells or organoids are widely used to study the role of genetic and environmental factors in human disease progression, which could provide a source of cells for large-scale drug discovery. Indeed, the chemical screens using hESC/iPSC-derived cells or organoids have identified candidates that help future drug development. In the meanwhile, these identified small molecules facilitate dissecting the molecular mechanism under pathological conditions. Most of current screens using hPSC-derived cells are phenotypic-based screens. Additional work needs to be done to further improve the throughput of these types of screens. Moreover, hPSC-derived 3D organoids show large variation due to their complicated structure. Appropriate assays need to be designed to adapt the organoid-based screen to a high-throughput/content manner. Finally, initial attempts of humanized mice have proven the power of this innovative model to evaluate long-term drug efficacy on human cells *in vivo*. Improved humanized mouse models, which contain multiple human organs, and/or the human immune system, will facilitate establishing more predictive *in vivo* models for drug discovery.

In summary, screening-based chemical approaches have been proven to be a powerful tool for controlling stem cell fate decisions, as well as decoding complicated disease progression. With the discovery of novel hPSC differentiation strategies, disease models, and humanized mouse models, the high-throughput/content chemical screens will significantly contribute to the discovery of a novel "toolkit" for regenerative medicine and precision therapy.
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